Generative AI-Supported Personalized Education Compared With Printed Material for Adults With Hypertension (GenAI-HYPER)

August 18, 2026 updated by: Akdeniz University

The Effect of Generative Artificial Intelligence-Supported Personalized Education Compared With Printed Material on Hypertension Knowledge and Medication Adherence in Adults With Hypertension

This study evaluates whether generative artificial intelligence-supported personalized education can improve hypertension knowledge and medication adherence in adults with hypertension compared with standard printed educational material. A total of 88 adults with hypertension are included in the study. Participants are assigned to either an intervention group or a control group. The control group receives a printed hypertension education booklet. The intervention group receives personalized educational content prepared using generative artificial intelligence based on individual characteristics and needs, together with weekly WhatsApp or SMS messages, voice messages, and brief telephone follow-up. The intervention lasts four weeks, and final assessments are performed in the fifth week. Hypertension knowledge, medication adherence self-efficacy, and blood pressure are assessed before and after the intervention. It is expected that personalized education will improve hypertension knowledge and medication adherence compared with printed education.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

88

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey (Türkiye)
    • Antalya
      • Antalya, Antalya, Turkey (Türkiye), 07070
        • Akdeniz University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Voluntary agreement to participate in the study
  • Diagnosis of hypertension
  • Use of antihypertensive medication for at least 6 months
  • Medication adherence self-efficacy score of 26 or lower
  • Age 18 years or older
  • Ability to read and write in Turkish
  • General health status adequate for communication
  • Ability to read SMS messages and use WhatsApp

Exclusion Criteria:

  • Withdrawal from the study after enrollment
  • Inability to be reached by telephone during the follow-up period

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: control group
Participants in this arm receive standard hypertension education and a printed hypertension education booklet. Baseline assessments and blood pressure measurements are performed in the first week. In the fifth week, post-intervention assessments and blood pressure measurements are repeated.
Behavioral: Standard Hypertension Education
Participants receive standard hypertension education including medication-related information and a printed hypertension education booklet developed based on expert recommendations.
Experimental: intervention group
Participants in this arm receive generative artificial intelligence-supported personalized hypertension education based on their individual characteristics, needs, baseline information, and the standardized hypertension education content. The intervention is delivered over four weeks through weekly WhatsApp or SMS messages and voice messages. Brief structured telephone follow-up is conducted during the first and fourth weeks. In the fifth week, post-intervention assessments and blood pressure measurements are performed.
Behavioral: Generative AI-Supported Personalized Hypertension Education
Participants receive personalized hypertension education generated using generative artificial intelligence based on individual characteristics, needs, baseline information, and standardized hypertension education content. The intervention is delivered over four weeks through weekly WhatsApp or SMS messages and voice messages. Brief structured telephone follow-up is provided in the first and fourth weeks.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mean Change From Baseline in Medication Adherence Self-Efficacy Scale-Short Form (MASES-SF) Total Score at Week 5
Time Frame: Baseline and Week 5
Medication adherence self-efficacy will be assessed using the 13-item Medication Adherence Self-Efficacy Scale-Short Form (MASES-SF). Each item is scored from 1 (not at all sure) to 4 (very sure), resulting in a total score ranging from 13 to 52. Higher scores indicate greater self-efficacy for adhering to antihypertensive medication. The change in total score from baseline to Week 5 will be evaluated.
Baseline and Week 5
Mean Change From Baseline in Hypertension Knowledge-Level Scale (HK-LS) Total Score at Week 5
Time Frame: Baseline and Week 5
Hypertension knowledge will be assessed using the 22-item Hypertension Knowledge-Level Scale (HK-LS). The scale includes six domains: definition, medical treatment, medication adherence, lifestyle, diet, and complications. Responses are recorded as true, false, or do not know, and each correct response receives 1 point. Higher scores indicate greater hypertension knowledge, and a score of 16 or above indicates a high level of hypertension knowledge. The change in total score from baseline to Week 5 will be evaluated.
Baseline and Week 5

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mean Change From Baseline in Systolic Blood Pressure at Week 5
Time Frame: Baseline and Week 5
Systolic blood pressure will be measured in mmHg at baseline and Week 5. The change in systolic blood pressure from baseline to Week 5 will be evaluated.
Baseline and Week 5
Mean Change From Baseline in Diastolic Blood Pressure at Week 5
Time Frame: Baseline and Week 5
Diastolic blood pressure will be measured in mmHg at baseline and Week 5. The change in diastolic blood pressure from baseline to Week 5 will be evaluated.
Baseline and Week 5

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Akdeniz University

Investigators

  • Principal Investigator: Yasemin DEMİR AVCI, PhD, Akdeniz University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 1, 2026

Primary Completion (Estimated)

December 20, 2026

Study Completion (Estimated)

December 20, 2026

Study Registration Dates

First Submitted

August 18, 2026

First Submitted That Met QC Criteria

August 18, 2026

First Posted (Actual)

August 20, 2026

Study Record Updates

Last Update Posted (Actual)

August 20, 2026

Last Update Submitted That Met QC Criteria

August 18, 2026

Last Verified

August 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • AKDENIZU-TBAEK-711

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe